Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study

JCO Precision Oncology · Published 2026-06-01 · DOI 10.1200/po-25-01285

Free full text

Authors (17)

Joyce O'Shaughnessy, Adam Brufsky, Rakhshanda Layeequr Rahman, Cynthia R. Osborne, Reshma Mahtani, Ahmed Elkhanany, Cathy Lynne Graham, Eric Brown, Linsey P. Gold, Nathalie Johnson, Danilo Giffoni, J. Jaime Alberty-Oller, Harshini Ramaswamy, Raquel Weber, Nicole Chmielewski-Stivers, Andrea R. Menicucci, William Audeh

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

O'Shaughnessy, J., Brufsky, A., Rahman, R., et al. (2026). Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study. JCO Precision Oncology. https://doi.org/10.1200/po-25-01285

Related articles